213 related articles for article (PubMed ID: 26773812)
21. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
[TBL] [Abstract][Full Text] [Related]
22. Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin.
Sheng X; Parmentier JH; Tucci J; Pei H; Cortez-Toledo O; Dieli-Conwright CM; Oberley MJ; Neely M; Orgel E; Louie SG; Mittelman SD
Mol Cancer Res; 2017 Dec; 15(12):1704-1713. PubMed ID: 29117945
[TBL] [Abstract][Full Text] [Related]
23. Chalcone inhibition of anthracycline secondary alcohol metabolite formation in rabbit and human heart cytosol.
Silvestrini A; Meucci E; Vitali A; Giardina B; Mordente A
Chem Res Toxicol; 2006 Nov; 19(11):1518-24. PubMed ID: 17112240
[TBL] [Abstract][Full Text] [Related]
24. Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin.
Bains OS; Takahashi RH; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2008 May; 36(5):904-10. PubMed ID: 18276838
[TBL] [Abstract][Full Text] [Related]
25. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Dec; 335(3):533-45. PubMed ID: 20837989
[TBL] [Abstract][Full Text] [Related]
26. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
Bukum N; Novotna E; Morell A; Hofman J; Wsol V
Chem Biol Interact; 2019 Apr; 302():101-107. PubMed ID: 30703376
[TBL] [Abstract][Full Text] [Related]
27. Anthracyclines, proteasome activity and multi-drug-resistance.
Fekete MR; McBride WH; Pajonk F
BMC Cancer; 2005 Sep; 5():114. PubMed ID: 16159384
[TBL] [Abstract][Full Text] [Related]
28. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
Wasowska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
Anticancer Res; 2006; 26(3A):2009-12. PubMed ID: 16827137
[TBL] [Abstract][Full Text] [Related]
29. Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro.
Takahashi RH; Bains OS; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2008 Jun; 36(6):991-4. PubMed ID: 18322072
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity.
Swift L; McHowat J; Sarvazyan N
Cancer Res; 2003 Sep; 63(18):5992-8. PubMed ID: 14522926
[TBL] [Abstract][Full Text] [Related]
31. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin.
Bains OS; Szeitz A; Lubieniecka JM; Cragg GE; Grigliatti TA; Riggs KW; Reid RE
J Pharmacol Exp Ther; 2013 Nov; 347(2):375-87. PubMed ID: 23995598
[TBL] [Abstract][Full Text] [Related]
32. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
33. Fibrates in the chemical action of daunorubicin.
Balendiran GK
Curr Cancer Drug Targets; 2009 May; 9(3):366-9. PubMed ID: 19442055
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of daunorubicin analogues containing truncated aromatic cores and unnatural monosaccharide residues.
Fan E; Shi W; Lowary TL
J Org Chem; 2007 Apr; 72(8):2917-28. PubMed ID: 17373847
[TBL] [Abstract][Full Text] [Related]
35. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance.
Veitch ZW; Guo B; Hembruff SL; Bewick AJ; Heibein AD; Eng J; Cull S; Maclean DA; Parissenti AM
Pharmacogenet Genomics; 2009 Jun; 19(6):477-88. PubMed ID: 19440163
[TBL] [Abstract][Full Text] [Related]
36. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.
Schott B; Robert J
Biochem Pharmacol; 1989 Nov; 38(22):4069-74. PubMed ID: 2597184
[TBL] [Abstract][Full Text] [Related]
37. The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro.
Schröterová L; Kaiserová H; Baliharová V; Velík J; Gersl V; Kvasnicková E
Physiol Res; 2004; 53(6):683-91. PubMed ID: 15588138
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of new derivatives of emodin.
Teich L; Daub KS; Krügel V; Nissler L; Gebhardt R; Eger K
Bioorg Med Chem; 2004 Nov; 12(22):5961-71. PubMed ID: 15498672
[TBL] [Abstract][Full Text] [Related]
39. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
40. Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol.
Olson RD; Li X; Palade P; Shadle SE; Mushlin PS; Gambliel HA; Fill M; Boucek RJ; Cusack BJ
Toxicol Appl Pharmacol; 2000 Dec; 169(2):168-76. PubMed ID: 11097869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
